Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Demystifying the KDQOL-36 and using it to plan patient care.

Witten B.

Nephrol News Issues. 2012 Nov;26(12):40, 42, 49. No abstract available.

PMID:
23472554
2.

Medicare Part D: challenges for dialysis patients (part 2 of 2): opportunities to improve patient experiences.

Smith S, Witten B, Paykin C, Weiner S, Chianchiano D, St Peter WL.

Nephrol News Issues. 2011 Dec;25(13):24, 26-9. No abstract available.

PMID:
22308830
3.

Medicare Part D: challenges for dialysis patients. Part 1.

Smith S, Witten B, Paykin C, Weiner S, Chianchiano D, St Peter WL.

Nephrol News Issues. 2011 Nov;25(12):38-40, 42, 44-5.

PMID:
22204167
4.

Challenges and opportunities in modality options education.

Campbell A, Witten B.

Nephrol News Issues. 2011 Nov;25(12):11-3. No abstract available.

PMID:
22204161
5.

Tungsten toxicity.

Witten ML, Sheppard PR, Witten BL.

Chem Biol Interact. 2012 Apr 5;196(3):87-8. doi: 10.1016/j.cbi.2011.12.002. Epub 2011 Dec 13. Review.

PMID:
22182474
6.

Insights into nephrologist training, clinical practice, and dialysis choice.

Merighi JR, Schatell DR, Bragg-Gresham JL, Witten B, Mehrotra R.

Hemodial Int. 2012 Apr;16(2):242-51. doi: 10.1111/j.1542-4758.2011.00649.x.

PMID:
22151183
7.

Part 2. The promise of symptom-targeted intervention to manage depression in dialysis patients: improving mood and quality of life outcomes.

Sledge R, Aebel-Groesch K, McCool M, Johnstone S, Witten B, Contillo M, Hafner J.

Nephrol News Issues. 2011 Jun;25(7):24-8, 30-1.

PMID:
21736132
8.

The promise of symptom-targeted intervention to manage depression in dialysis patients.

McCool M, Johnstone S, Sledge R, Witten B, Contillo M, Aebel-Groesch K, Hafner J.

Nephrol News Issues. 2011 May;25(6):32-3, 35-7.

PMID:
21608458
9.

Factors affecting employment at initiation of dialysis.

Muehrer RJ, Schatell D, Witten B, Gangnon R, Becker BN, Hofmann RM.

Clin J Am Soc Nephrol. 2011 Mar;6(3):489-96. doi: 10.2215/CJN.02550310. Epub 2011 Mar 10.

10.

Vocational rehabilitation: is your facility on track?

Hall L, Gore S, Witten B.

Nephrol News Issues. 2009 Dec;23(13):22-5.

PMID:
20050435
11.

The Missouri Kidney Program's Patient Education Program: a 12-year retrospective analysis.

King K, Witten B, Brown JM, Whitlock RW, Waterman AD.

Nephrol News Issues. 2008 Nov;22(12):44-5, 48-52, 54.

PMID:
19105516
12.

Why we need a health-related quality of life CPM.

Stec P, Schatell D, Witten B.

Nephrol News Issues. 2008 Mar;22(3):28-30, 35. Review. No abstract available.

PMID:
18372678
13.

Why measure quality in kidney disease?

Robinson K, Schatell D, Witten B.

Nephrol News Issues. 2007 Apr;21(5):38-9. No abstract available.

PMID:
17427440
14.

Developing effective kidney patient education materials.

Schatell D, Witten B.

Nephrol News Issues. 2006 Aug;20(9):53, 55. No abstract available.

PMID:
16916065
15.

Medicare prescription drug coverage (part D): challenges and opportunities.

Witten B.

Nephrol News Issues. 2006 Aug;20(9):14-6, 18. Review. No abstract available.

PMID:
16916055
16.

Part I--Medicare prescription drug coverage (Part D): the promise.

Witten B.

Nephrol News Issues. 2006 Jul;20(8):14, 17-8. No abstract available.

PMID:
16859229
17.

Kidney patient job retention: the next rehabilitation frontier.

Schatell D, Witten B.

Nephrol News Issues. 2006 Apr;20(4):47-8, 62. Review. No abstract available.

PMID:
16629357
18.

Dialysis patient empowerment: what, why, and how.

Schatell D, Witten B.

Nephrol News Issues. 2005 Aug;19(9):37-9. No abstract available.

PMID:
16173302
19.

Anemia: dialysis patients experiences.

Schatell D, Witten B.

Nephrol News Issues. 2004 Nov;18(12):49-54. No abstract available.

PMID:
15595502
20.

Improving employment outcomes: the renal care team's role.

Witten B, Howell P, Latos D.

Nephrol News Issues. 1999 Mar;13(3):46-8. No abstract available.

PMID:
10382490
21.
22.
23.

Disaster preparedness for renal facilities and patients.

Letteri JM, Adams MB, Duffy M, Fedje L, Jacobs C, Kaysen G, Krohn BA, Norwood K, O'Connor P, Schiereth M, Witten B.

Ren Fail. 1997 Sep;19(5):673-85. Review. No abstract available.

PMID:
9380886
24.

Improving quality of care and social work outcomes in dialysis.

Callahan MB, Witten B, Johnstone S.

Nephrol News Issues. 1997 Feb;11(2):40-3. No abstract available.

PMID:
9096465
25.

Maintaining employment: a valuable rehabilitation tool.

Witten B.

Nephrol News Issues. 1994 Aug;8(8):22-3. No abstract available.

PMID:
7969547
26.

Patient access and expectations of nephrology social workers.

Siegal BR, Witten B, Lundin AP.

Nephrol News Issues. 1994 Apr;8(4):32-3, 40. No abstract available.

PMID:
8177340
27.

Conceptions of rape.

Remer R, Witten BJ.

Violence Vict. 1988 Fall;3(3):217-32.

PMID:
3154181
29.

The endometrial biopsy as a guide to the management of luteal phase defect.

Witten BI, Martin SA.

Fertil Steril. 1985 Oct;44(4):460-5.

PMID:
4054317
30.

Delivering human services for abused clients: a system and individual approach.

Emener WG Jr, Stilwell WE, Witten BJ.

Fam Community Health. 1981 Aug;4(2):71-83. No abstract available.

PMID:
10252188
31.

Otoplasty--an eclectic technique.

Maniglia AJ, Maniglia JJ, Witten BR.

Laryngoscope. 1977 Aug;87(8):1359-68.

PMID:
329023
32.

Diffuse otitis externa: clinical and microbiologic findings in the course of a multicenter study on a new otic solution.

Cassisi N, Cohn A, Davidson T, Witten BR.

Ann Otol Rhinol Laryngol Suppl. 1977 May-Jun;86(3 Pt 3 Suppl 39):1-16.

PMID:
194524
33.

Pathologic quiz case 2.

Witten BR.

Arch Otolaryngol. 1974 Jul;100(1):76-8. No abstract available.

PMID:
4842618
34.

Extracellular toxic reactions of some sulfur and nitrogen mustards.

Williamson CE, Seligman AM, Witten B.

J Pharmacol Exp Ther. 1972 Jul;182(1):77-82. No abstract available.

PMID:
5041657
35.

Enzyme alterable alkylating agents. XI. Clinical trials of an esterase-susceptible water-soluble agent (S-73) for regional chemotherapy.

Bakal D, Goodman LE, Ulfohn A, Mamaril AG, Caplan YH, Calle S, Bhagavan BS, Witten B, Williamson CE, Sass S, Seligman AM.

J Surg Res. 1971 May;11(5):217-23. No abstract available.

PMID:
5090338
36.

Enzyme alterable alkylating agents. X. Experimental study of an esterase-susceptible water-soluble agent (S-73) for regional chemotherapy.

Ulfohn A, Kramer SP, Calle S, Sass S, Williamson CE, Witten B, Seligman AM.

J Surg Res. 1968 Aug;8(8):345-59. No abstract available.

PMID:
5667860
37.

Synthesis of potential anticancer agents.

Williamson CE, Sayers TJ, Seligman AM, Witten B.

J Med Chem. 1967 May 1;10(3):511. doi: 10.1021/jm00315a061. No abstract available.

PMID:
22185177
38.

Preliminary study of an esterase-susceptible water-soluble agent (S-73) for regional chemotherapy.

Goodman LE, Ulfohn A, Kramer SP, Calle S, Bakal D, Madamba R, Witten B, Williamson CE, Sass S, Seligman AM.

Cancer. 1967 May;20(5):826-8. No abstract available.

PMID:
6024292
39.

Reaction mechanism of some aromatic nitrogen mustards.

Williamson CE, Witten B.

Cancer Res. 1967 Jan;27(1):33-8. No abstract available.

40.

Enzyme-alterable alkylating agents. IX. The enzymatic transformation of some nitrogen mustards in the presence of carbon dioxide: implications in respiration.

Williamson CE, Kirby JG, Miller JI, Sass S, Kramer SP, Seligman AM, Witten B.

Cancer Res. 1966 Feb;26(2):323-30. No abstract available.

41.

Enzyme alterable alkylating agents. 8. Clinical trials with intra-arterial infusion of an alkylating agent with a half-life of 0.2 second.

Goodman LE, Ulfohn A, Kramer SP, Cendana EH, Flores AB, Bakal D, Abrams SJ, Hirschfeld RL, Calle S, Williamson CE, Sass S, Witten B, Seligman AM.

Ann Surg. 1965 Oct;162(4):663-89. No abstract available.

42.

ENZYME-ALTERABLE ALKYLATING AGENTS. VII. THE DESIGN OF SHORT-LIVED MUSTARDS.

SASS S, WILLIAMSON CE, KRAMER SP, GOODMAN LE, ULFOHN A, SELIGMAN AM, WITTEN B.

J Med Chem. 1965 Jan;8:14-7. No abstract available.

PMID:
14287258
43.

THE DURATION OF THE MYELOTOXIC EFFECTS OF CIRCULATING ALKYLATING AGENTS.

ULFOHN A, KRAMER SP, DORFMAN H, WITTEN B, WILLIAMSON C, SASS S, MILLER JI, SELIGMAN AM.

Cancer Res. 1964 Oct;24:1659-65. No abstract available.

44.

A NEW BIOLOGIC REACTION OBSERVED WITH SECONDARY NITROGEN MUSTARDS NOR-HN2 (NSC-10873) AND MANNITOL MUSTARD (NSC-9698).

WILLIAMSON CE, KIRBY JG, MILLER JI, SASS S, KRAMER SP, SELIGMAN AM, WITTEN B.

Cancer Chemother Rep. 1964 Sep;41:47-9. No abstract available.

PMID:
14213142
45.

ENZYME ALTERABLE ALKYLATING AGENTSVI. SYNTHESIS, CHEMICAL PROPERTIES, TOXICITIES, AND CLINICAL TRIAL OF HALOACETATES AND HALOACETAMIDES CONTAINING ENZYME-SUSCEPTIBLE BONDS.

KRAMER SP, GOODMAN LE, DORFMAN H, SOLOMON R, RUTENBURG AM, PINEDA E, NASONLLULFOHN A, GABY SD, BAKAL D, WILLIAMSON CE, MILLER JI, SASS S, WITTEN B, SELIGMAN AM.

J Natl Cancer Inst. 1963 Aug;31:297-327. No abstract available.

PMID:
14046627
46.

ENZYME ALTERABLE ALKYLATING AGENTS. V. DESIGN OF SULFUR MUSTARDS WITH VARYING DEGREES OF HYDROLYTIC STABILITY IN A SEARCH FOR SHORT BIOLOGICAL HALF-LIFE AGENTS.

WILLIAMSON CE, MILLER JI, SASS S, CASANOVA J, KRAMER SP, SELIGMAN AM, WITTEN B.

J Natl Cancer Inst. 1963 Aug;31:273-96. No abstract available.

PMID:
14046626
48.

Enzyme-alterable alkylating agents. III. Synthesis, chemical properties, and toxicities of mustards containing enzyme-susceptible ester bonds.

WITTEN B, SASS S, MILLER JI, WILLIAMSON CE, GUERRERO HG, KRAMER SP, SOLOMON RD, GOODMAN LE, SELIGMAN AM.

Cancer. 1962 Sep-Oct;15:1062-72. No abstract available.

PMID:
14007766
49.

New short half-life alkylating agents for intra-arterial regional chemotherapy.

WITTEN B, WILLIAMSON CE, MILLER JI, SASS S, KRAMER SP, GOODMAN LE, ULFOHN A, SELIGMAN AM.

Cancer Chemother Rep. 1962 Feb;16:515-6. No abstract available.

PMID:
14007767
50.

Effective use of a new alkylating agent in doses lethal to bone marrow with protection by tourniquets of marrow in the extremis.

GOODMAN LE, SCHILLING A, KRAMER SP, ULFOHN A, MILLER S, KRAVITZ S, GABY SD, BAKAL D, WITTEN B, SELIGMAN AM.

Surg Forum. 1961;12:130-2. No abstract available.

PMID:
13900321

Supplemental Content

Loading ...
Support Center